Endoscopic sphincterotomy before fully covered self-expandable metal stent placement for malignant extrahepatic biliary obstruction to prevent pancreatitis: a randomised controlled trial

Published: 18-01-2016 Last updated: 15-05-2024

To investigate the role of endoscopic sphincterotomy prior to biliary fully covered SEMS (FCSEMS) placement in the prevention of post-ERCP pancreatitis.

Ethical review Approved WMO **Status** Recruitment stopped

Health condition type Gastrointestinal inflammatory conditions

Study type Interventional

Summary

ID

NL-OMON55849

Source

ToetsingOnline

Brief title

Sphinx

Condition

- Gastrointestinal inflammatory conditions
- Gastrointestinal neoplasms malignant and unspecified

Synonym

Post-ERCP pancreatitis

Research involving

Sponsors and support

Primary sponsor: Academisch Medisch Centrum **Source(s) of monetary or material Support:** Wij hebben een subsidieaanvraag ingediend bij COOK Medical en zijn in afwachting van een reactie.

Intervention

Keyword: endoscopic sphincterotomy, extrahepatic cholestasis, post-ERCP pancreatitis, stents

Outcome measures

Primary outcome

Incidence of post-ERCP pancreatitis.

Secondary outcome

- 30-day morbidity related to ERCP (with or without sphincterotomy)
- Technical success of stent placement
- Stent-related 30-day morbidity
- 30-day mortality

Study description

Background summary

Self-expandable metal stents (SEMSs) are increasingly being used to treat malignant common bile duct obstruction. This shift towards SEMS placement (and away from plastic stent placement) is accompanied by a change in the complication profile of biliary stent placement, with a sharp decrease in late occlusion and cholangitis, but a slight increase in the incidence of post-ERCP pancreatitis. It is hypothesised that endoscopic sphincterotomy before biliary SEMS placement may reduce the occurrence of post-ERCP pancreatitis by widening the orifice of the major duodenal papilla and reducing compression of the pancreatic sphincter. Data on whether or not to perform ES are conflicting. As a result, the European guideline leaves pre-stenting biliary sphincterotomy to the preference of the endoscopist.

Study objective

To investigate the role of endoscopic sphincterotomy prior to biliary fully covered SEMS (FCSEMS) placement in the prevention of post-ERCP pancreatitis.

Study design

A multicentre, open, randomised controlled trial.

Intervention

Patients will be randomised to FCSEMS placement with or without prior endoscopic biliary sphincterotomy.

Study burden and risks

All patients are consented for ERCP, and for the study, and informed about the complications associated with an ERCP: abdominal pain, bleeding, post-ERCP pancreatitis and perforation (consent for ERCP). The main risks of endoscopic sphincterotomy are haemorrhage (2.0%) and perforation (0.3%). In daily practice, whether or not the patient will be subjected to a sphincterotomy depends on the endoscopist*s preference. Therefore, the study does not introduce an additional risk for the participant.

The presumed benefit of an endoscopic sphincterotomy is a reduction in the post-ERCP pancreatitis rate after biliary SEMS placement, but sphincterotomy may be accompanied by an increased risk of bleeding and perforation. Therefore, a change in the distribution of complications could be anticipated. The burden for patients participating in this trial is small, with only two short telephone calls seven and thirty days after the procedure to evaluate possible procedure-related complications.

Contacts

Public

Academisch Medisch Centrum

Meibergdreef 9 Amsterdam 1105 AZ NI

Scientific

Academisch Medisch Centrum

Meibergdreef 9 Amsterdam 1105 AZ

3 - Endoscopic sphincterotomy before fully covered self-expandable metal stent place ... 1-06-2025

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- Indication for fully covered self-expandable metal stent placement
- (Suspected) malignant biliary outflow obstruction
- Biliary stenosis located >= 2 cm distal from the hilum
- Age >= 18 years
- Written informed consent for the procedure and study participation

Exclusion criteria

- Hilar biliary obstruction, defined as stenosis located within 2 cm of the hilum
- Biliary SEMS or more than 1 plastic endoprothesis in situ
- Precut sphincterotomy or standard sphincterotomy
- Prophylactic pancreatic duct stent, even when the PD-stent is subsequently removed
- Continued use of anticoagulants or antiplatelet drugs with the exception of low-dose aspirin (max. 100 mg/day)
- Known clotting disorder
- Patients unable to provide written consent for the study

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Primary purpose: Prevention

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 03-05-2016

Enrollment: 511

Type: Actual

Ethics review

Approved WMO

Date: 18-01-2016

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 23-12-2016

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 16-10-2017

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 25-09-2018

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 08-10-2018

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 02-11-2018

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 28-01-2019

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 25-02-2019

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 30-04-2019

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 20-05-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 06-08-2020
Application type: Amendment

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 21209

Source: Nationaal Trial Register

Title:

In other registers

Register ID

CCMO NL54248.018.15
OMON NL-OMON21209